<DOC>
	<DOC>NCT00543205</DOC>
	<brief_summary>This is an open-label, parallel-group study with a total of 16 evaluable subjects. Subjects will be assigned to 1 of the following cohorts: Cohorts I (subjects with normal hepatic function; n+8 and Cohort II (subjects with moderate hepatic impairment, Child-Pugh classification Grade B; n=8). If, for any reason, the Genasense infusion is interrupted or discontinued prior to completion or the rate of administration of the Genasense infusion is changed, the subject will be replaced.</brief_summary>
	<brief_title>Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirmed diagnosis of malignant melanoma Metastatic Stage IV disease, or Stage III disease that is not surgically resectable ECOG Performance status of 0,1,or 2 Adequate venous access Agreement to practice effective methods of birth control Hepatically impaired consistent with ChildPugh classification Grade B Chronic intravascular coagulopathy confirmed by the presence of fibrinogen degradation products, metastases to the liver, or exudative ascites Prior organ allograft Requirement for concomitant anticoagulant therapy (with the exception of 1 mg/day of warfarin for central line prophylaxis) while receiving protocol therapy Known hypersensitive to DTIC Prior treatment with Genasense</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>